ClinicalTrials.gg
CompletedNCT05595655Updated Jan 26, 2023

Randomized Controlled Trial to Test the Efficacy of Motivational Interviewing on Self-care

An interventional study of Motivational Interviewing in Heart Failure, sponsored by Azienda Socio Sanitaria Territoriale di Lodi. Completed at 1 site in Italy. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Azienda Socio Sanitaria Territoriale di Lodi · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 5 years 4 months after the study started (first participant enrolled May 2017, registered Oct 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Sex
All
01

Study summary

Introduction: Heart failure (HF) is characterized by an increasing prevalence and burden, representing a public health problem and a major cause of morbidity and mortality. Self-care is a cornerstone approach for optimizing therapy for patients with HF; patients play a key role in the management of their condition, given that several negative health outcomes might be avoided with effective self-care. Motivational interviewing (MI) has been described by the literature as highly favorable for treating chronic diseases, with promising results supporting its efficacy in enhancing self-care. Moreover, caregivers' availability constitutes a fundamental supporting factor among the strategies to improve self-care behaviors in people with HF.

Methods and analysis: This study protocol designed a prospective, parallel-arm, open-label, three-arm, controlled trial for purposing the aims to test the efficacy of a structured program including scheduled MI interventions in improving self-care behaviors among patients with HF at 3, 6, 9, and 12 months from the enrolment. Secondary aims comprehend the corroboration of the superiority of caregivers' participation to the structured program including scheduled MI interventions over the program administrated only to individual patients in enhancing self-care behaviors and other outcomes. Analyses will be performed within the framework of intention-to-treat (ITT). Comparisons between groups will be based on an alpha = 5% and two-tailed null hypotheses. In the case of missingness, analyzing the extent of the missingness and identifying underlying mechanisms and patterns will guide imputation methods.

Ethics and dissemination: The study protocol and template consent forms have been reviewed and approved by the Ethical Committee of San Raffaele Hospital (approval #74/INT). Also, the study protocol has been registered at ClinicalTrials.gov (Identifier: .......). Patients and caregivers will have to sign the informed consent forms before the randomisation. Patients and caregivers may leave the study at any time. The withdrawal from the study will not imply any prejudice, as fully documented and explained in the informed consent. Considering the open-access publication, the full protocol will be available freely.

02

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • heart failure
  • motivational interviewing
  • self-care
03

In context

Heart Failure

6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

This study's enrollment of 180 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Azienda Socio Sanitaria Territoriale di Lodi is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥ 18 years;
  • diagnosis of HF with (NYHA) Class II-IV;
  • no acute coronary events within three months;
  • consent to participate in the study;
  • score ≤ 2 to at least two items of the Self-Care of Heart Failure Index 6.2 - SCHFI 6.2 at baseline;
  • score on Six Item Screener > 4;
  • living at home;
  • understanding of spoken and written Italian.

Exclusion criteria

Exclusion Criteria:

  • severe cognitive impairment (score 0-4 on the Six-item Screener);
  • acute coronary events that occurred within three months;
  • living in nursing homes or residential settings;
  • caregivers unwilling to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • No intervention
    control group

    The dyads will receive traditional educational treatment only and will complete the questionnaires after 3, 6, 9 and 12 months follow-up post-intervention. Enrolled dyads will be monitored by the research team responsible for recruitment and follow-up.

  • Other
    First interventional arm

    MI intervention will be administered to patients only and caregivers will receive standard education. The intervention will last approximately 30 minutes. Thereafter, the nurse who performed the MI will contact the patients over the phone 3 times during the first 2 months after MI, to strengthen the intervention. Then, the intervention will be employed again after 3, 6, 9 and 12 months from enrolment. After each MI session, both patients and caregivers will be asked to complete the questionnaires of follow-up post-intervention

    Behavioral: Motivational Interviewing

  • Experimental
    Second interventional arm

    MI intervention will be administered both to patients and caregivers. The intervention will be administered to the dyad in one session and patients and their caregivers will receive the reinforcing educational treatment calibrated on the specific lacking areas of patients' self-care behaviours. After each MI session, both patients and caregivers will be asked to complete the questionnaires of follow-up post-intervention.

    Behavioral: Motivational Interviewing

Interventions

  • BehavioralMotivational Interviewing

    Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.

06

What researchers measure

Primary outcomes

  1. Changes will be assessed in the Level of self-care maintenance - Self-Care of Heart Failure Index 6.2

    self-care behavior consisting in keeping the disease stable

    Time frame: 3, 6, 9, and 12 months from the enrollment

Secondary outcomes

  1. Changes will be assessed in the Level of caregivers' involvement - Caregiver Contribution to Self-care of Heart Failure Index (CC-SCHFI)

    superiority of the caregivers' participation to the structured program including scheduled MI interventions over the program administrated only to individual patients in enhancing self-care behaviors

    Time frame: 3, 6, 9, and 12 months from the enrollment

  2. Changes will be assessed in the Level of patient's ability to feel the symptoms of HF - Heart Failure Somatic Perception Scale (HFSPS)

    patient's ability perceive the symptoms of HF

    Time frame: 3, 6, 9, and 12 months from the enrollment

  3. Changes will be assessed in the Level of cognitive impairment- Six Item Screener

    patients' cognitive impairment

    Time frame: 3, 6, 9, and 12 months from the enrollment

  4. Changes will be assessed in the Level of physical function, symptoms, social function, self-efficacy, and quality of life (QoL) - Kansas City Cardiomyopathy Questionnaire (KCCQ)

    HF-specific QoL

    Time frame: 3, 6, 9, and 12 months from the enrollment

  5. Changes will be assessed in the Level of feeling of intimacy and positive relationship between patient and caregiver -Mutuality Scale (MS)

    feeling of intimacy and positive relationship between patient and caregiver

    Time frame: 3, 6, 9, and 12 months from the enrollment

  6. Changes will be assessed in the Level of physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health - SF-12

    generic health-related QoL

    Time frame: 3, 6, 9, and 12 months from the enrollment

  7. Changes will be assessed in the Level of presence of significant sleep disturbance experienced in the month before the assessment - Pittsburgh Sleep Quality Index (PSQI)

    sleep quality

    Time frame: 3, 6, 9, and 12 months from the enrollment

  8. Changes will be assessed in the Level of depression and anxiety - Hospital Anxiety and Depression Scale (HADS)

    depression and anxiety

    Time frame: 3, 6, 9, and 12 months from the enrollment

  9. Changes will be assessed in the Level of cognitive impairment - Montreal Cognitive Assessment (MoCA)

    mild cognitive impairment

    Time frame: 3, 6, 9, and 12 months from the enrollment

  10. Changes will be assessed in the Number of comorbidities - Charlson Comorbidity Index (CCI)

    comorbidities

    Time frame: 3, 6, 9, and 12 months from the enrollment

  11. Changes will be assessed in the Level of caregiver contribution to self-care - Caregiver Contribution to Self-care of Heart Failure Index (CC-SCHFI)

    caregiver contribution to self-care in patients with HF

    Time frame: 3, 6, 9, and 12 months from the enrollment

  12. Changes will be assessed in the Level of caregiver Preparedness - Caregiver Preparedness Scale (CPS)

    Caregiver Preparedness to care

    Time frame: 3, 6, 9, and 12 months from the enrollment

  13. Changes will be assessed in the Level of social support - Multidimensional Scale of Perceived Social Support (MSPSS)

    level of social support perceived by HF patients in managing the disease

    Time frame: 3, 6, 9, and 12 months from the enrollment

07

Study locations

1 site
  • Cardiology
    Lodi, Milan 26903, Italy
08

References and documents

Individual participant data

Plan to share: Undecided — raw data sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in May 2020, 36 months.

Of 1,118 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 36 months is above that.

Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Oct 27, 2022
StartActual
May 27, 2017
Primary completionActual
May 30, 2020
CompletionActual
May 17, 2021
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05595655
Lead sponsor
Azienda Socio Sanitaria Territoriale di Lodi
Responsible party
Greta Ghizzardi (Principal Investigator, Azienda Socio Sanitaria Territoriale di Lodi) — Principal investigator
First posted
Oct 27, 2022
Start date
May 27, 2017
Primary completion
May 30, 2020
Completion
May 17, 2021
Last update
Jan 26, 2023

Study contacts

Federica Dellafiore
principal investigator · Università degli Studi di Pavia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion